Log in to save to my catalogue

Long COVID — metabolic risk factors and novel therapeutic management

Long COVID — metabolic risk factors and novel therapeutic management

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8054121

Long COVID — metabolic risk factors and novel therapeutic management

About this item

Full title

Long COVID — metabolic risk factors and novel therapeutic management

Publisher

London: Nature Publishing Group UK

Journal title

Nature reviews. Endocrinology, 2021-07, Vol.17 (7), p.379-380

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Cardiometabolic conditions, including type 1 and type 2 diabetes mellitus, are associated with severe COVID-19 and long COVID. Interventions to target multiple risk factors, combined with use of novel glucose-lowering agents that improve metabolic function and the key processes that are impaired in COVID-19, should be the preferred therapeutic opti...

Alternative Titles

Full title

Long COVID — metabolic risk factors and novel therapeutic management

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8054121

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8054121

Other Identifiers

ISSN

1759-5029

E-ISSN

1759-5037

DOI

10.1038/s41574-021-00495-0

How to access this item